A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma

Mesothelioma Clinical Trial

— SKOPOS  

Official title:

A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01569919
• Other study ID #: 2010/VCC/0049
• Secondary ID: 2010-023230-22
• Status: Recruiting
• Phase: Phase 2
• First received: March 28, 2012
• Last updated: March 11, 2013
• Start date: December 2012
• Est. completion date: December 2014

Study information

• Verified date: March 2013
• Source: Wales Cancer Trials Unit
• Contact: Hayley Clements, BSc
• Phone: +442920687500
• Email: skopos[@]cardiff.ac.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This study is for patients with malignant mesothelioma of the lung lining (called pleura) who are planning to have pemetrexed-cisplatin chemotherapy.

We are investigating whether giving a vaccine called TroVax® with pemetrexed-cisplatin chemotherapy is both safe and potentially beneficial in patients with mesothelioma. This vaccine has been used in combination with chemotherapy in other types of cancer and has been shown to be safe. Cancer vaccines work by stimulating the person's immune system to fight the disease, in a similar way to the immune system fighting infection. In laboratory experiments, the vaccine has been shown to stimulate an immune response to a particular protein widely found on mesothelioma cells called 5T4. In patients with mesothelioma it is hoped that the vaccine will stimulate the immune system to attack mesothelioma cells carrying the 5T4 protein.

Pemetrexed-cisplatin chemotherapy is currently seen as the best treatment for patients with mesothelioma, and this is why we plan to combine it with the vaccine. It is hoped that the combination of the TroVax® vaccine and chemotherapy is more beneficial than chemotherapy alone.

Pemetrexed-cisplatin will be given into a vein in the arm (intravenously) every 3 weeks. The TroVax® vaccine will be given as an injection into the shoulder muscle (intramuscularly) 3 weeks before chemotherapy starts, one week before chemotherapy starts, then every 3 weeks. Each participant will receive 4 chemotherapy and 9 vaccine treatments if they complete the planned trial schedule. We aim to recruit 26 patients into the trial over a two year period. If this study shows that pemetrexed-cisplatin chemotherapy plus the TroVax® vaccine is safe and beneficial in terms of stimulating the immune system, the combination will be tested further in larger clinical trials.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 26
• Est. completion date: December 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated written informed consent obtained from the patient in accordance with the local regulations

• Locally advanced or metastatic, histologically or cytologically proven MPM

• Aged 18 years or over

• WHO performance status 0-1 (Appendix I)

• Life expectancy > 6months

• Haemoglobin = 12 g/dl, total white cell count = 3 x 10^9/L, neutrophil count > 1.5 x 10^9/L, lymphocyte count =1 x 10^9/L, monocyte count <0.8 x 10^9/L platelet count >100 x 10^9/L and <400 x 10^9/L. Blood transfusion is allowed.

• Adequate renal function: Creatinine = 50 mL/min as measured by EDTA or 60mL/min as measured by the Cockcroft-Gault formula

• Adequate liver function: ALT, AST and bilirubin < 2 times the upper limit of normal

• At least four weeks from any previous therapy including surgery, or radiotherapy

• Able to comply with the protocol

• Women must be either post-menopausal, or rendered surgically sterile or, if of child-bearing potential, must have a negative pregnancy test prior to trial entry. Two reliable forms of contraception (oral contraception and a barrier method) must be used by all participants while they are being treated with the TroVax® vaccine. Females must continue to use this level of contraception for 3 months following the last trial treatment, and male patients must continue for 1 month.

Exclusion Criteria:

• Serious infections within the 28 days prior to entry to the trial.

• Prior TroVax® treatment

• Previous chemotherapy for MPM

• Major surgery or radiation therapy completed = 4 weeks prior to enrolment

• Prior radiopharmaceuticals (strontium, samarium) less than 8 weeks prior to enrolment

• Participation in any other clinical trial of a licensed or unlicensed drug within the previous 30 days

• History of prior malignant disease unless patient has been disease-free for at least 3 years or the tumour was a non-melanoma skin cancer or early cervical cancer

• Autoimmune disease including systemic Lupus Erythematosis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis, insulin dependent diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease

• Clinical significant cardiac failure or a measured ejection fraction of <40%

• Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the patient inappropriate for entry into this study.

• Chronic corticosteroid use unless prescribed as replacement therapy in the case of adrenal insufficiency, or other immunosuppressive agents. Dexamethasone is allowed as part of trial treatment.

• Cerebral metastases

• History of allergic response to previous vaccine vaccinations

• Known allergy to egg proteins

• Known to test positive for HIV or hepatitis B or C

• Pregnancy or lactation

• Prior history of organ transplantation

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Malignant
• Mesothelioma
• Pleural

Intervention

Biological:
• TroVax®
Dose of 1 x 10^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.

Drug:
• Pemetrexed
500 mg/m^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
• Cisplatin
75mg/m^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13

Dietary Supplement:
• Vitamin B12
1000µg intramuscular, Day 2 of weeks 3 and 12
• Folic Acid
400µg oral daily from Day 2 of week 3 to Day 2 of week 16

Drug:
• Dexamethasone
4mg BD, Days 2-6 of weeks 4, 7, 10, 13

Locations

Country	Name	City	State
United Kingdom	Velindre Cancer Centre	Cardiff	South Wales

Sponsors (4)

Lead Sponsor	Collaborator
Wales Cancer Trials Unit	June Hancock Mesothelioma Research Fund, Velindre Cancer Centre Stepping Stones Appeal, Velindre NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immune response to 5T4 and MVA antigens as measured by intracellular cytokine staining (ICCS)	To evaluate whether TroVax® is active in the treatment of MPM. This will be assessed by measuring the cellular or humoral anti-5T4 immune responses following treatment with TroVax® given in combination with Pem/Cis.	34 weeks	No
Secondary	Safety and tolerability	To investigate the safety and tolerability of TroVax® in combination with Pem/Cis. This will be assessed from toxicity data, SAE reports and dose of chemotherapy received	34 weeks	Yes
Secondary	Clinical activity in terms of PFS, ORR and OS	To assess secondary measures of clinical activity, including progression-free survival (PFS), objective response rate (ORR), overall survival (OS) at 6 months and 1 year	1 year	No
Secondary	Relationship between immune response and clinical response	To explore the relationship between immune response (antibody and cellular responses against the tumour 5T4 and the MVA viral vector) and clinical response (PFS, ORR, OS).	1 year	No
Secondary	Identify potential predictors of treatment benefit	To investigate the utility of (a) baseline platelet levels, (b) baseline monocyte levels and (c) baseline haemoglobin as predictors of treatment benefit.	1 year	No

External Links

•   Wales Cancer Trials Unit